KOSPIBiotech & Pharma019170

Shinpoong Pharmaceutical

₩7,370▼ 1.60%2026-11-18 close
Market Cap
₩386.3B
Turnover
₩500M
Volume
70K
Shares out.
52.4M
PER
—
PBR
1.5×
EPS
-₩357
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Three Straight Quarterly Operating Losses; FY2026 Is the Next Test

Shinpoong Pharmaceutical returned to annual operating profit in 2025, but operating losses have continued for three straight quarters through the third quarter of 2026, and third-quarter revenue fell 18.1% year on year.

  1. 1

    Operating profit of KRW 14.3 billion in 2025 (operating margin 6.1%) reversed three years of operating losses.

  2. 2

    Cumulative January–September 2026 revenue of KRW 169.7 billion fell 3.9% year on year, leaving a gap against the 11% growth target set for 2026.

  3. 3

    The third quarter of 2026 posted an operating loss of KRW 4.44 billion and a controlling-shareholder net loss of KRW 11.8 billion, both reversing prior-year profits.

  4. 4

    Higher selling and administrative costs from the introduction of a CSO (contract sales organization) worsened first-half 2026 operating results, while a KRW 60 billion global production base investment is under way.

  5. 5

    Because the last four quarters show net losses, the price-to-earnings ratio is not calculated, and the price-to-book ratio sits above 1x.

02

Business structure

Shinpoong Pharmaceutical was founded in 1962 with a primary aim of pharmaceutical manufacturing and listed on the Korea Stock Exchange in 1990, making it a mid-sized pharmaceutical company.

Its core business covers finished and active pharmaceutical ingredient manufacturing and sales, and it reaches overseas markets through six overseas subsidiaries in Vietnam, the Philippines, Myanmar and the United States.

Its flagship product is the malaria treatment Pyramax, and because of its earlier clinical work on COVID-19 treatment, the company is often grouped with infectious-disease treatment themes whenever those issues resurface. Its in-house pipeline includes a cardiovascular new drug candidate.

The company is working to shift from a generic-centered structure toward new drugs. Selling costs rose in the first half of 2026 after the company introduced a CSO, with higher severance and commission costs lifting selling and administrative expenses.

In January 2026 the company terminated an exclusive supply agreement with GreenPine Pharma Group, a Chinese partner, and said the termination caused no financial loss because no revenue had been recorded under it. The company has also outlined a KRW 60 billion investment to build a global production base.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩62.6B₩7.2B11.5%
2025Q4₩58B₩3.9B6.7%
2026Q1₩54.5B-₩400M−0.7%
2026Q2₩63.9B-₩8B−12.6%
2026Q3₩51.3B-₩4.4B−8.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩209.3B-₩34B-₩35.4B−16.3%−10.7%9.3%
2023₩200.2B-₩47.4B-₩57.3B−23.7%−21.3%29.3%
2024₩221.1B-₩20.5B-₩15.4B−9.3%−6.0%32.5%
2025₩234.7B₩14.3B₩8.8B6.1%3.3%30.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue fell from KRW 209.3 billion in 2022 to KRW 200.2 billion in 2023 (down 4.3% year on year), then rose to KRW 221.1 billion in 2024 (up 10.4%) and KRW 234.7 billion in 2025 (up 6.1%), marking two consecutive years of growth from the 2023 low. 2025 was the largest year within 2022–2025.

Operating losses widened from KRW 34 billion in 2022 to KRW 47.4 billion in 2023, then narrowed to KRW 20.5 billion in 2024, before the company swung to an operating profit of KRW 14.3 billion in 2025. The operating margin moved from -16.3% in 2022 and -23.7% in 2023 to -9.3% in 2024 and 6.1% in 2025.

Controlling-shareholder net income turned positive at KRW 8.83 billion in 2025, while net income including non-controlling interests was KRW 8.39 billion. Operating cash flow was negative from 2022 to 2024 and turned positive at KRW 17.3 billion in 2025.

The debt ratio rose from 9.3% in 2022 to 30.2% in 2025, with total liabilities of KRW 81.7 billion and total equity of KRW 270.7 billion at the end of 2025.

On a quarterly basis, revenue slowed from KRW 62.6 billion in the third quarter of 2025 to KRW 58 billion in the fourth quarter, then fell to KRW 54.5 billion in the first quarter of 2026 with an operating loss of KRW 363 million.

The second quarter of 2026 revenue rose 17.2% quarter on quarter to KRW 63.9 billion, yet the operating loss widened to KRW 8.03 billion. The third quarter brought revenue of KRW 51.3 billion, down 18.1% year on year, and an operating loss of KRW 4.44 billion that was smaller than the second quarter's loss.

Controlling-shareholder net losses were KRW 8.01 billion in the second quarter and KRW 11.8 billion in the third quarter of 2026. The combined controlling-shareholder net loss for the last four quarters was KRW 19 billion.

05

Industry analysis

Korea's pharmaceutical and biotech sector is clearly shifting its center of gravity from generic-based revenue toward in-house new drugs and overseas expansion. Shinpoong's 2026 New Year message set out a new mid-to-long-term growth vision and stressed R&D competitiveness and new product results.

In this transition, clinical, regulatory and selling costs often rise before revenue catches up. The CSO introduction in the first half of 2026 that lifted selling and administrative expenses reads in the same context.

Pharmaceutical companies' earnings paths can shift sharply with clinical outcomes and approval timing, so quarterly profit swings tend to be large. Companies with prior COVID-19 treatment work are also often grouped into infectious-disease themes, so share price moves and reported results can diverge.

Among listed peers such as Hanmi Pharm, Yuhan and SAM Chun Dang Pharm, comparisons typically center on new drug pipeline scale and technology transfer results. For Shinpoong, the most relevant comparison points are the pace of revenue growth and the recovery of operating margin. This section interprets the company's own disclosed results rather than sector-wide figures.

06

Outlook

The company has described 2026 as the first year of sustained growth and said it will set a new mid-to-long-term growth vision. The 2026 revenue target was presented as an 11% increase over the prior year, alongside a stated aim to build a foundation for sustainable profitable operations.

A KRW 60 billion global production base is presented as the means of executing this plan. Among in-house pipeline assets, a cardiovascular drug candidate has been cited, and generating new product results is positioned as a core task.

However, cumulative January–September 2026 revenue fell 3.9% year on year, and third-quarter revenue declined 18.1%, widening the gap to the annual target. On the cost side, the CSO introduction is cited as a factor in the first-half operating loss.

The third-quarter operating loss narrowed to KRW 4.44 billion from KRW 8.03 billion in the second quarter, but the three-quarter run of operating losses remains intact. Termination of the Chinese partner agreement removed one overseas revenue path, with delayed Chinese regulatory approval given as the reason.

The 2026 annual report will be the first periodic filing that shows full-year revenue and operating margin against the target.

07

Valuation

PER
—
PBR
1.5×
ROE
-7.1%
EPS
-₩357
BPS
₩5,070
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the last four quarters show net losses, which makes earnings-based multiples hard to compare with past levels. The price-to-book ratio sits above 1x, meaning the shares trade at a premium to book value.

This gap reflects an asset base of about KRW 270 billion in controlling-shareholder equity at the end of 2025 against weaker earnings power in 2026. The dividend yield is effectively negligible, so dividend-based comparison does not apply.

The share price has repeatedly swung sharply with infectious-disease headlines, and multiples moved widely regardless of reported earnings, including a short-term surge tied to COVID-19 resurgence concerns in August 2026.

Around past swings from losses to profit, the direction of earnings recovery has served as the reference point for reading multiples. Valuation interpretation therefore rests on comparing the durability of earnings recovery with the asset base.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Return to profit and positive operating cash flow in 2025

Full-year 2025 operating profit of KRW 14.3 billion reversed prior losses, with an operating margin of 6.1%. Operating cash flow also turned positive at KRW 17.3 billion in 2025, ending the negative trend that ran from 2022. Controlling-shareholder net income turned to a profit of KRW 8.83 billion in the same year. Improvement in both earnings and cash flow is the factual basis for reading a change in the business structure.

In-house pipeline and production base investment

The company has framed 2026 as the first year of sustained growth and plans to invest KRW 60 billion in a global production base. Its cardiovascular drug candidate and other in-house pipeline assets are in progress, pointing to an effort to move beyond a generics-centered structure. If new product results are confirmed, they could diversify the revenue mix, which forms the bullish case.

A balance sheet with equity larger than liabilities

At the end of 2025, total liabilities were KRW 81.7 billion and total equity was KRW 270.7 billion, so equity remained larger than liabilities. The debt ratio rose from 9.3% in 2022 to 30.2% in 2025 but the equity base still supports the structure.

Controlling-shareholder equity of KRW 270 billion forms most of total equity, providing a basis for financial cushion.

09

Bear factors

Three straight quarters of operating losses

Operating losses persisted from the first quarter through the third quarter of 2026, and the third-quarter operating loss of KRW 4.44 billion reversed a prior-year operating profit of KRW 7.22 billion.

Controlling-shareholder net losses of KRW 8.01 billion in the second quarter and KRW 11.8 billion in the third quarter extended a two-quarter losing streak. The combined controlling-shareholder net loss for the last four quarters was KRW 19 billion, so earnings recovery has been slow.

Gap between revenue growth target and actual results

Early in 2026 the company set a revenue target of 11% growth over the prior year. However, cumulative January–September 2026 revenue of KRW 169.7 billion fell 3.9% year on year. Third-quarter revenue declined 18.1% year on year, adding pressure on reaching the annual target.

Overseas agreement termination and higher selling costs

The exclusive supply agreement with GreenPine Pharma Group, a Chinese partner, was terminated in January 2026. Cited reasons included delays in China's CFDA approval process and additional research costs.

Severance and commission costs from the CSO introduction raised selling and administrative expenses, which the company cites as a cause of the operating loss.

10

Risk factors

Share price volatility from infectious-disease themes

Each time COVID-19 resurgence concerns emerge, treatment-related trading themes tend to attract capital, increasing share price volatility. A short-term surge tied to such concerns appeared in August 2026.

Flows unrelated to reported earnings can distort multiples, so tracking earnings and price separately helps in reading the facts.

Overseas approval and contract timing risk

A Chinese supply agreement was terminated after CFDA approval procedures were delayed. Longer approval timelines add research costs and time, which can change the business case. Overseas approval timing directly affects the company's overseas revenue path.

Investment burden and cash flow durability

The KRW 60 billion production base investment overlaps with higher selling costs from the CSO introduction. Operating cash flow was KRW 17.3 billion positive in 2025, but that was a single year, so its durability will show in upcoming periodic reports.

Equity size cushions the balance sheet, though financial pressure could increase depending on the pace of investment.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    The 2026 annual report will show how close full-year revenue came to the 11% growth target and whether the operating margin stayed positive. These are the next checkpoints.

  2. Around May 15, 2027 (Q1 quarterly report deadline)

    Whether first-quarter 2027 operating results return to profit after the KRW 4.44 billion operating loss in the third quarter of 2026, and whether CSO-related selling costs decline, will mark the first test of earnings recovery.

  3. After December 2026 (ad hoc disclosures)

    Progress on the KRW 60 billion global production base and clinical or regulatory disclosures on in-house pipeline assets are the checkpoints for new product results.

12

Overall view

Shinpoong Pharmaceutical returned to an operating profit of KRW 14.3 billion in 2025 and its operating cash flow turned positive. However, operating losses have continued for three straight quarters from the first quarter through the third quarter of 2026, and third-quarter revenue fell 18.1% year on year.

Cumulative January–September 2026 revenue fell 3.9%, leaving a gap against the 11% growth target for 2026. The bullish side rests on the return to profit, improved cash flow, the in-house pipeline and the KRW 60 billion production base investment.

The bearish side rests on higher selling costs, the terminated overseas agreement and a KRW 19 billion combined controlling-shareholder net loss over the last four quarters. On valuation, the price-to-earnings ratio cannot be calculated because of recent net losses, while the price-to-book ratio sits above 1x.

The share price has swung sharply with infectious-disease headlines, so its link to reported earnings is weak. The next checkpoints are full-year revenue and operating margin in the 2026 annual report, and whether first-quarter 2027 operating results return to profit.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.wisereport.co.kr
  2. monews.co.kr
  3. vegannews.co.kr
  4. thebionews.net
  5. seo.goover.ai
  6. m.news.nate.com
  7. pflow.keywordegg.com
  8. finance.eduinfom.com
  9. catch.co.kr
  10. alphadistill.com
  11. paxnet.co.kr
  12. kr.investing.com
  13. judal.co.kr
  14. kr.investing.com
  15. kr.investing.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis